ASH 2022 | Phase II study of E7820 in patients with splicing factor-mutant myeloid malignancies
Jan Bewersdorf
• 11 Dec 2022
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, comments on the results of a Phase II study evaluating the safety and efficacy of E7820 in splicing factor-mutant myeloid malignancies (NCT05024994). While the study did not report improvement in terms of efficacy, the treatment was well-tolerated. In addition, pre-clinical data has shown that it might be beneficial to combine E7820 with immune checkpoint inhibitors. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
